Cost Savings Calculator

 

This simple-to-use calculator will help you better understand the financial impact of central line catheter occlusions on your institution. Neutron can help reduce these costs by helping to reduce the overall incidence of central line catheter occlusions.

Calculator instructions Expand

tPA & Connector Costs

 
 
 

Enter your values  

Number of central line catheters placed in your facility each year

#

Percentage of central lines that require tPA1,2 More info Expand

%

Total tPA cost per treatment3 More info Expand

$

If applicable in your facility, list additional costs of your (tPA) protocol including:

$

  • Travel time (if applicable for homecare or infusion center)
  • Unscheduled nursing visit
  • Ancillary supplies
 

tPA reduction using Neutron (estimated 50%)4

%

Cost per connector (not Neutron)

$

Cost per Neutron

$

Number of connectors per line More info Expand

#

 

Additional Clinical Costs of Catheter Occlusion

 

tPA success rate5 More info Expand

%

PICC/CVC replacement cost6,7,8

$

Increased length of stay (days) More info Expand

#

Cost per day / increased treatment costs9 More info Expand

$

 
 

 

Detailed Summary

Expand
 

References

  1. Haire WD, Atkinson JB, Stephen LC, Kotulak GD, et al. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost. 1994;72(4):543-7.
  2. Deitcher S, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol. 2002;20(1): 317-24.
  3. Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL, Klang M, Lucarelli CD, Muller RJ, Eng SL, Connor M, Small TN, Brown AE, Saltz LB. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices, JCO. Apr 1, 2002:1918-1922; DOI:10.1200/JCO.2002.07.131.
  4. Observational in-vivo evaluation of the Neutron™ needlefree catheter patency device and its effects on catheter occlusions in a home care setting. Study Summary. ICU Medical.
  5. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER; COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001 Aug;12(8):951-5
  6. Kokotis K. Cost containment and infusion services. Journal of Infusion Nursing. (2005) 28(3 Suppl.), S22-S32.
  7. Cummings-Winfield C, Mushani-Kanji T. Restoring patency to central venous access devices. Clin J Oncol Nurs. 2008; 12(6):925-934.
  8. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep. 2002;51(RR-10):1-26.
  9. The Kaiser Family Foundation statehealthfacts.org. "Hospital Adjusted Expenses per Inpatient Day, 2009." Data Source: AHA Annual Surveys. ©2011 by Health Forum LLC, an affiliate of the American Hospital Association.